ITRM Insider Trading Activity and SEC Form 4 Filings
ITRM insider trading summary
Over the past 12 months, insiders at Iterum Therapeutics plc (ITRM) reported 1 open-market purchase worth $2K by 1 insider and no sales on SEC Form 4. Net insider buying was $2K.
Latest ITRM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 18, 2025 | Michael W. Dunne | Insider | Buy | $2K (6,000 @ $0.37) |
| Aug 8, 2025 | Michael W. Dunne | Insider | Buy | $11K (15,000 @ $0.72) |
| Dec 22, 2023 | Michael W. Dunne | Director | Buy | $35K (25,000 @ $1.40) |
| Dec 18, 2023 | Michael W. Dunne | Director | Buy | $18K (10,000 @ $1.84) |
| Nov 22, 2023 | Michael W. Dunne | Director | Buy | $41K (20,000 @ $2.03) |
| Nov 20, 2023 | Corey N. Fishman | Chief Executive Officer | Buy | $16K (10,000 @ $1.59) |
| Dec 2, 2022 | Sailaja Puttagunta | Chief Medical Officer | Sell | $4K (3,365 @ $1.32) |
| Sep 20, 2022 | Brenton Karl Ahrens | Director | Sell | $13K (7,246 @ $1.78) |
| Sep 19, 2022 | Brenton Karl Ahrens | Director | Sell | $26K (15,000 @ $1.77) |
| Sep 16, 2022 | Brenton Karl Ahrens | Director | Sell | $29K (15,000 @ $1.90) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.